IN8bio Presents Promising Clinical Trial Results

IN8bio ( (INAB) ) has issued an announcement.

IN8bio, Inc. presented data from its Phase 1 and Phase 2 clinical trials of INB-200 and INB-400 at the 2025 Society for Neuro-Oncology Annual Meeting. The trials involved 17 patients treated with the company’s DeltExTM Drug Resistant Immunotherapy, showing promising results with a median progression-free survival of 13.0 months compared to 6.6 months for standard-of-care patients. The median overall survival for treated patients has not been reached and continues to improve, currently at 16.4+ months, whereas standard-of-care patients reached a median overall survival of 11.0 months.

The most recent analyst rating on (INAB) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on IN8bio stock, see the INAB Stock Forecast page.

Spark’s Take on INAB Stock

According to Spark, TipRanks’ AI Analyst, INAB is a Underperform.

IN8bio’s stock score reflects significant financial challenges, typical of early-stage biotechnology companies. The financial performance is hindered by substantial operational losses and reliance on external funding, while technical analysis shows bearish market trends. Valuation remains speculative with a negative P/E ratio, emphasizing the high-risk nature of investing in developmental biotech firms.

To see Spark’s full report on INAB stock, click here.

More about IN8bio

IN8bio, Inc. operates in the biotechnology industry, focusing on developing innovative immunotherapies. The company specializes in gamma-delta T cell therapies, particularly targeting glioblastoma, a form of brain cancer.

Average Trading Volume: 66,618

Technical Sentiment Signal: Sell

Current Market Cap: $7.88M

For detailed information about INAB stock, go to TipRanks’ Stock Analysis page.